Humacyte, Inc. recently announced the presentation of results from the V007 phase 3 clinical trial of the company’s acel ...

November 13, 2024—R3 Vascular Inc. recently announced that the FDA granted investigational device exemption (IDE) approval to initiate the company’s ELITE-BTK pivotal trial of Magnitude, its ...

November 11, 2024—iVascular announced the initiation of OPAL, a first-in-human study of Amber, the company’s embolic liquid ...

CVRx, Inc. announced recently that the Centers for Medicare and Medicaid Services (CMS) assigned the company’s Barostim p ...

Medtronic and Recor Medical, Inc. (and its parent company, Otsuka Medical Devices Co., Ltd.) separately and independently ...

A nationwide retrospective study evaluated health care resource utilization and outcomes among patients with intermediate-risk ...

Akura Medical, a Shifamed portfolio company focused on venous thromboembolism care, announced recently that the FDA has approve ...

A study assessed the effects of intravascular volume expansion on deep pelvic vein size using the 200-150-125 rule for the ...

DEEPER OUS is a prospective, nonrandomized, multicenter, single-arm trial taking place in New Zealand, Germany, and Switzerland ...

Secondary outcomes through 6 months were reported from the VenaSeal Spectrum Surgical Stripping study, a randomized ...

In the LIFE-BTK trial, several initiatives were implemented to facilitate enrollment of diverse populations, ensuring that pati ...

The final results from the DETOUR2 study evaluated the durability of percutaneous transmural arterial bypass (PTAB) using the D ...